Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review

Kwaśny, Aleksander; Kwaśna, Julia; Wilkowska, Alina; Szarmach, Joanna; Słupski, Jakub; Włodarczyk, Adam; Cubała, Wiesław Jerzy

doi:10.1016/j.euroneuro.2024.04.014

European Neuropsychopharmacology

2024

DOI: 10.1016/j.euroneuro.2024.04.014

|View full text |Cite

Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review

Aleksander Kwaśny,

Julia Kwaśna,

Alina Wilkowska

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression

Kumar,

Menon,

Andrade

2024

Asian Journal of Psychiatry

View full text Add to dashboard Cite

A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression

Kumar,

Menon,

Andrade

2024

Asian Journal of Psychiatry

View full text Add to dashboard Cite

The Search for Consistency in Residual Symptoms in Major Depressive Disorder: A Narrative Review

Pastuszak,

Cubała,

Kwaśny

et al. 2024

JPM

View full text Add to dashboard Cite

Residual symptoms are prevalent in major depressive disorder (MDD), encompassing a wide spectrum of symptoms such as sleep disturbances, changes in weight and appetite, cognitive impairment, and anxiety. These symptoms consistently impair daily functioning, diminish quality of life, and forecast disease relapse. Despite their clinical significance, residual symptoms lack a unified definition, potentially leading to confusion with treatment-emergent symptoms and ambiguity across studies, thereby hindering the generalizability of research findings. While some research identifies insomnia and mood disturbances as critical indicators, other studies emphasize different symptoms or find no significant correlation. Inconsistencies in defining residual symptoms, as well as methodological differences across studies, contribute to these conflicting results. While clinicians focus on alleviating negative symptoms to improve functional status, patients often prioritize achieving positive affect and overall well-being as essential components of successful treatment. It necessitates a comprehensive approach to patient care in depression. This review explores the phenomenon of residual symptoms in MDD, focusing on the ambiguity in definitions, clinical characteristics, and their impact on long-term outcomes. The lack of a standardized regulatory or academic definition for residual symptoms leads to varied interpretations among clinicians, underscoring the need for standardized terminology to guide effective treatment strategies and future research.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review

Cited by 2 publications

References 75 publications

A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression

A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression

The Search for Consistency in Residual Symptoms in Major Depressive Disorder: A Narrative Review

Contact Info

Product

Resources

About